Trump's likely pick for Ambassador knows a lot about India

Agencies
June 23, 2017

Washington, Jun 23: After five months without a U.S. number one in India, Donald Trump appears to have finally chosen the next ambassador to the subcontinent. Kenneth Juster, who serves as a top deputy at the National Economic Council in Trump's White House, will likely exert a steadying influence on U.S.-India relations if his nomination goes forward as expected.Donald

Juster is a long-time India hand - he chaired the U.S.-India High Technology Cooperation Group and helped spearhead a major new bilateral initiative under the George W. Bush administration - and with his extensive diplomatic experience, he differs from some of Trump's other ambassadorial picks such as Terry Branstad, the former Iowa governor, or Callista Gingrich, his envoy to the Vatican.

That would be a balm for Indians ahead of Prime Minister Narendra Modi's first meeting with Trump on June 26 in Washington.

"If Ken Juster is named, the Indians will be pleased about that because he is a known quantity," said Tanvi Madan, director of the India Project at the Brookings Institution. "In a time of a lot of uncertainty, his appointment would be a reassurance."

"He's considered an experienced hand with a good relationship in the White House and other agencies that will make him an effective ambassador," said Ronak D. Desai, a U.S.-India relations expert at Harvard University and fellow at New America.

Rumors swirled in May that Juster was out as Trump's G7 chief negotiator amid personal tensions with other White House staff but was under consideration for India ambassador. Confirmation of his apparently likely nomination was reported in the Washington Post on June 21.

The State Department declined to comment.

If Juster is tapped for the post, he'll have to navigate some significant political minefields, in large part thanks to his former boss in the Oval Office. One key sticking point is climate change. Trump angered the entire world when he pulled out of the Paris climate agreement, and went out of his way to jab India in the process.

He falsely claimed India had only signed onto the agreement for billions of dollars in subsidies in a speech on June 1 announcing his withdrawal. "That rubbed India the wrong way," said Desai. India "invested a lot and went out on a ledge" to back the U.S.-brokered Paris climate agreement.

There's more irritants than just Paris. A spate of attacks on Indian-Americans since Trump came into office has also caused consternation in the subcontinent. And modifications to make it harder for highly-skilled workers overseas to get U.S. visas - part of the Trump White House's "America First" plan, which big tech companies don't like - could hit India hard.

But if anything has chafed Modi, he hasn't let it show publicly. "[India] has very studiously avoided criticizing Trump in a manner other world leaders have done in the past four to five months," said Desai.

Some blame the attacks on Indian-Americans on the racially-charged climate Trump churned up on the campaign trail - and he's been silent on the attacks ever since despite growing concerns among Indians and Indian-Americans.

"Given the very real fears of Indian-Americans and the crucial role of the Indian diaspora in U.S.-India relations, Modi can't afford not to bring up this matter," wrote the Wilson Center's Michael Kugelman.

But Trump's overall policy towards India has yet to take shape. Modi and former President Barack Obama enjoyed a strong personal rapport that boosted bilateral relations during his term. The litmus test for Modi's relationship with Trump comes Monday, when they meet for the first time in Washington.

The two leaders are expected to discuss terrorism, trade, and Indo-Pacific security issues, with an eye on China's growing assertiveness in the Indian Ocean, where the United States and India are cooperating more. Trump jarred the world with his rejection of multilateral free trade deals, excoriating China for what he called unfair trade practices that harm American workers.

India has so far avoided similar ire. Last year, trade between the two nations totalled almost $115 billion; the United States imported about $31 billion more from India than it exported. Commerce Secretary Wilbur Ross has previously signalled that the administration is open to discussing a free trade agreement with the world's sixth-largest economy, though there seems to be little momentum in that direction. (India was not a part of the Trans-Pacific Partnership, the 12-nation trade deal Trump pulled out of.)

But unlike China, Saudi Arabia, the Persian Gulf states, and Turkey, India is not a big player on issues like Syria or North Korea - the issues the Trump administration cares most about. That will make Modi work to capture Trump's interest.

"The question will be, what level of attention does India get?" said Madan.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
March 15,2020

Jakarta, Mar 15: Indonesia's transport minister is in intensive care after testing positive for the novel coronavirus, an official has said, as schools and tourist attractions were ordered to close over the health threat.

Transportation Minister Budi Karya Sumadi was receiving treatment at an army hospital in Jakarta, State Secretary Pratikno said on Saturday.

A hospital spokesman said Sumadi was encountering difficulty breathing but that his condition was improving.

Pratikno said Sumadi was involved in virus mitigation efforts, particularly the evacuation of Indonesians from epicenters of the outbreak, and that President Joko Widodo had called for tests to be carried out on other ministers.

Cases of the virus in Indonesia, the world's fourth most populous country, have jumped from zero two weeks ago to 96, with five deaths, according to government spokesperson Achmad Yurianto.

He also said the virus has spread outside Greater Jakarta to Bandung in West Java, Solo in Central Java, Manado in North Sulawesi, Pontianak in West Kalimantan, as well as holiday havens Yogyakarta and Bali.

Following the increase, the government on Saturday established a task force on COVID-19 mitigation.

Jakarta's Governor Anies Baswedan announced that schools would close for two weeks starting Monday, and ordered the closure of city-owned tourist attractions, such as Ragunan Zoo and Ancol beach.

He emphasized that Jakarta would not be locked down but urged people "to be responsible" and called for social distancing when possible.

Similarly, the administration of Solo, Central Java, Friday announced that schools and tourist attractions would close after a coronavirus patient died in the region.

The World Health Organization has said it is particularly concerned about high-risk nations with weaker health systems, which who may lack the facilities to identify cases.

A day after declaring the coronavirus outbreak to be pandemic this week, WHO chief Tedros Adhanom Ghebreyesus called Indonesia's president Widodo and both agreed to "scale up cooperation."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 25,2020

Hubei, Mar 25: As a bus departed from its terminus at Hankou Railway Station at 5:25 am Wednesday morning, Wuhan started to resume bus service after nine weeks of lockdown.

Apart from a driver, a safety supervisor was also on each bus, whose duty was to make sure all passengers are healthy.
"For those who do not use smartphones, they should bring with them a health certificate issued by the health authorities," said Zhou Jingjing, a safety supervisor aboard bus No. 511 departing from the Wuchang Railway Station complex.
The once hardest-hit city in central China's Hubei Province during the COVID-19 outbreak took unprecedented traffic restrictions on Jan 23. All of its public transport and all outbound flights and trains had been suspended in an attempt to contain the virus within the region.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.